OCULAR THERAPEUTIX, INC (OCUL) Form 10-Q — Nov 9, 2026
Ocular Therapeutix (OCUL) reported Q3 2026 DEXTENZA net product revenue of $12.9 million, down 11.0% year over year, driven by higher gross-to-net provisions (57.7% of gross sales vs. 52.5% a year ago). The net loss widened to $94.8 million in Q3 ($262.2 million for nine months) as R&D spend jumped 43% to $74.8 million on the AXPAXLI Phase 3 programs (SOL and HELIOS). Operating cash burn for the nine months was $198.9 million.
Key figures
- Revenue
- 37134000
- Total Debt
- 82474000
- Revenue Yoy
- -3.9% (nine months); product revenue $12.9M in Q3, down 11.0% YoY
- Total Assets
- 605647000
- Cash Position
- 530612000
- Shares Outstanding
- 220022840
- Q3 net loss
- 94782000
- Rd expense q3
- 74787000
- Gtn provisions q3
- 57.7%
- Accumulated deficit
- 1419180000
- Operating cash burn 9m
- 198888000
- In market sales q3 units
- 49000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.